Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas
Canadian Journal of Gastroenterology and Hepatology · 2026-01 · 2026 (1)
DOI: 10.1155/cjgh/8778095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 28.06.2026. Verfasst von Yi-Hao Yen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and, Chang Gung University College of Med…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Neoplasm Recurrence, Local, Radiofrequency Ablation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a lethal cancer. Early recurrence, i.e., recurrence within two years of curative treatment, is a major determinant of ultimate survival. Materials and Methods We included 625 patients with newly diagnosed early‐stage HCC, i.e., Barcelona Clinic Liver Cancer (BCLC) Stage 0 or A, and Child–Pugh Class A liver disease who underwent percutaneous radiofrequency ablation (RFA) between 2011 and 2021 at our institution with a follow‐up period of > 2 years. The patients were divided into Group 1 (patients who developed nonlocal recurrence or died within two years after RFA; n = 300 [48.0%]) and Group 2 (patients who developed local recurrence within two years or were recurrence‐free and were alive for two years after RFA; n = 325 [52.0%]).
Results
Multivariate analysis showed that a Model for End‐Stage Liver Disease (MELD) score of > 9, anti‐hepatitis C virus (HCV) positivity, the presence of image‐defined cirrhosis, treatment with antiviral therapies for hepatitis B virus or HCV, alpha‐fetoprotein ≥ 20 ng/mL, multiple tumors, and larger tumor size were independent factors associated with Group 1. A nomogram was developed based on these variables to predict Group 1, with a concordance index of 68.3% (95% CI = 64.1%–72.5%). The 10‐year overall survival of Group 1 was 28%, and that of Group 2 was 64%.
Conclusion
We developed a nomogram to predict true early recurrence (i.e., nonlocal recurrence) of HCC after RFA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and, Chang Gung University College of Medicine, Kaohsiung, Taiwan, cgu.edu.tw.
ORCID-Profile: Yi-Hao Yen, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Yen, Y. H., Kee, K. M., Hung, C. H., Chen, C. H., Hu, T. H., Wang, J. H., & Lu, S. N. (2026). Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas. Canadian Journal of Gastroenterology and Hepatology, 2026(1). https://doi.org/10.1155/cjgh/8778095
Vancouver
Yen YH, Kee KM, Hung CH, Chen CH, Hu TH, Wang JH, et al. Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas. Canadian Journal of Gastroenterology and Hepatology. 2026;2026(1). doi:10.1155/cjgh/8778095
BibTeX
@article{Yen2026,
author = {Yen, Yi-Hao and Kee, Kwong-Ming and Hung, Chao-Hung and Chen, Chien-Hung and Hu, Tsung-Hui and Wang, Jing-Houng and Lu, Sheng-Nan},
title = {Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjgh/8778095}
}
EUVIMED